Morgan Stanley
PLRX icon

Morgan Stanley’s Pliant Therapeutics PLRX Stock Holding History

Morgan Stanley’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$341K Sell
298,976
-206,763
-41% -$252K ﹤0.01% 5722
2026
Q1 		$637K Sell
505,739
-43,223
-8% -$54.6K ﹤0.01% 5369
2025
Q4 		$670K Sell
548,962
-2,958,326
-84% -$4.44M ﹤0.01% 5370
2025
Q3 		$5.19M Sell
3,507,288
-246,325
-7% -$376K ﹤0.01% 4119
2025
Q2 		$4.35M Buy
3,753,613
+702,099
+23% +$992K ﹤0.01% 4165
2025
Q1 		$4.12M Buy
3,051,514
+2,269,510
+290% +$13.8M ﹤0.01% 4091
2024
Q4 		$10.3M Sell
782,004
-35,119
-4% -$479K ﹤0.01% 3384
2024
Q3 		$9.16M Buy
817,123
+143,276
+21% +$1.79M ﹤0.01% 3497
2024
Q2 		$7.24M Buy
673,847
+289,745
+75% +$3.74M ﹤0.01% 3584
2024
Q1 		$5.72M Sell
384,102
-20,921
-5% -$345K ﹤0.01% 3809
2023
Q4 		$7.33M Buy
405,023
+311,020
+331% +$4.73M ﹤0.01% 3611
2023
Q3 		$1.63M Buy
94,003
+6,280
+7% +$109K ﹤0.01% 4515
2023
Q2 		$1.59M Sell
87,723
-197,741
-69% -$4.68M ﹤0.01% 4567
2023
Q1 		$7.59M Buy
285,464
+171,484
+150% +$4.88M ﹤0.01% 3398
2022
Q4 		$2.2M Sell
113,980
-99,713
-47% -$2.08M ﹤0.01% 4396
2022
Q3 		$4.46M Sell
213,693
-142,346
-40% -$2.72M ﹤0.01% 3790
2022
Q2 		$2.85M Buy
356,039
+33,275
+10% +$213K ﹤0.01% 4253
2022
Q1 		$2.26M Sell
322,764
-20,356
-6% -$208K ﹤0.01% 4423
2021
Q4 		$4.63M Buy
343,120
+191,875
+127% +$3.05M ﹤0.01% 3800
2021
Q3 		$2.55M Buy
151,245
+117,550
+349% +$2.49M ﹤0.01% 4374
2021
Q2 		$982K Buy
33,695
+29,372
+679% +$914K ﹤0.01% 5090
2021
Q1 		$170K Sell
4,323
-5,284
-55% -$172K ﹤0.01% 5756
2020
Q4 		$218K Sell
9,607
-6,649
-41% -$167K ﹤0.01% 5546
2020
Q3 		$368K Buy
16,256
+14,556
+856% +$364K ﹤0.01% 4793
2020
Q2 		$55K Buy
+1,700
New +$45.1K ﹤0.01% 5647

Other funds holding PLRX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $1.26B AUM 60.23% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

Morgan Stanley's PLRX Position: Q2 2026 in Review

Morgan Stanley reduced its Pliant Therapeutics (PLRX) stake by 41% in Q2 2026, selling an estimated $252K and leaving 298,976 shares worth $341K. The position accounts for ﹤0.01% of the portfolio, ranked #5722.

Morgan Stanley first reported a position in PLRX in Q2 2020 and has held it in 25 quarters since. The position peaked at $10.3M in Q4 2024. 86 funds tracked by Wall St. Rank hold PLRX as of Q2 2026.

  • Morgan Stanley held 298,976 shares of Pliant Therapeutics worth $341K as of Q2 2026.
  • Morgan Stanley sold 206,763 Pliant Therapeutics shares in Q2 2026, an estimated $252K.
  • Pliant Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #5722 holding.
  • Morgan Stanley first reported a position in Pliant Therapeutics in Q2 2020 and has held it in 25 quarters since.
  • Morgan Stanley's Pliant Therapeutics position peaked at $10.3M in Q4 2024.
  • 86 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.